These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 3741716)

  • 1. Sparteine oxidation polymorphism: a family study.
    Brøsen K; Otton SV; Gram LF
    Br J Clin Pharmacol; 1986 Jun; 21(6):661-7. PubMed ID: 3741716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sparteine oxidation polymorphism in Greenlanders living in Denmark.
    Brøsen K
    Br J Clin Pharmacol; 1986 Oct; 22(4):415-9. PubMed ID: 3768256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sparteine oxidation polymorphism in Denmark.
    Brøsen K; Otton SV; Gram LF
    Acta Pharmacol Toxicol (Copenh); 1985 Nov; 57(5):357-60. PubMed ID: 4090995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark.
    Drøhse A; Bathum L; Brøsen K; Gram LF
    Br J Clin Pharmacol; 1989 May; 27(5):620-5. PubMed ID: 2757884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imipramine metabolism in relation to the sparteine oxidation polymorphism--a family study.
    Madsen H; Hansen TS; Brøsen K
    Pharmacogenetics; 1996 Dec; 6(6):513-9. PubMed ID: 9014200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Genetic polymorphism in sparteine oxidation--occurrence in healthy volunteers in Slovakia].
    Holomán J; Glasa J; Veningerová M; Prachar V; Lukácsová M
    Bratisl Lek Listy; 1997 Feb; 98(2):86-90. PubMed ID: 9264814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steady-state plasma levels of clomipramine and its metabolites: impact of the sparteine/debrisoquine oxidation polymorphism. Danish University Antidepressant Group.
    Nielsen KK; Brøsen K; Gram LF
    Eur J Clin Pharmacol; 1992; 43(4):405-11. PubMed ID: 1451721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inter-ethnic difference in sparteine oxidation among Ghanaians and Germans.
    Eichelbaum M; Woolhouse NM
    Eur J Clin Pharmacol; 1985; 28(1):79-83. PubMed ID: 3987789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship between paroxetine and the sparteine oxidation polymorphism.
    Sindrup SH; Brøsen K; Gram LF; Hallas J; Skjelbo E; Allen A; Allen GD; Cooper SM; Mellows G; Tasker TC
    Clin Pharmacol Ther; 1992 Mar; 51(3):278-87. PubMed ID: 1531950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The genetic polymorphism of sparteine metabolism.
    Eichelbaum M; Reetz KP; Schmidt EK; Zekorn C
    Xenobiotica; 1986 May; 16(5):465-81. PubMed ID: 3739368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism.
    Brøsen K; Klysner R; Gram LF; Otton SV; Bech P; Bertilsson L
    Eur J Clin Pharmacol; 1986; 30(6):679-84. PubMed ID: 3533565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for polymorphic oxidation of sparteine in Japanese subjects.
    Ishizaki T; Eichelbaum M; Horai Y; Hashimoto K; Chiba K; Dengler HJ
    Br J Clin Pharmacol; 1987 Apr; 23(4):482-5. PubMed ID: 3580254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence for altered catalytic properties of the cytochrome P-450 involved in sparteine oxidation in poor metabolizers.
    Osikowska-Evers B; Dayer P; Meyer UA; Robertz GM; Eichelbaum M
    Clin Pharmacol Ther; 1987 Mar; 41(3):320-5. PubMed ID: 3816020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetically determined sparteine oxidation polymorphism in a Polish population.
    Orzechowska-Juzwenko K; Pawlik J; Niewiński P; Milejski P; Dembowski J; Turek J; Goździk A; Swiebodzki L; Hora Z
    Eur J Clin Pharmacol; 1994; 46(5):481-3. PubMed ID: 7957549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quinidine kinetics after a single oral dose in relation to the sparteine oxidation polymorphism in man.
    Brøsen K; Davidsen F; Gram LF
    Br J Clin Pharmacol; 1990 Feb; 29(2):248-53. PubMed ID: 2306418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism.
    Sindrup SH; Brøsen K; Gram LF
    Clin Pharmacol Ther; 1992 Mar; 51(3):288-95. PubMed ID: 1531951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.
    Broly F; Gaedigk A; Heim M; Eichelbaum M; Morike K; Meyer UA
    DNA Cell Biol; 1991 Oct; 10(8):545-58. PubMed ID: 1681816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sparteine oxidation polymorphism: phenotyping by measurement of sparteine and its dehydrometabolites in plasma.
    Paar WD; Schuhler H; Fimmers R; Dengler HJ
    Eur J Clin Pharmacol; 1989; 36(6):555-60. PubMed ID: 2590312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphic drug oxidation in humans.
    Eichelbaum M
    Fed Proc; 1984 May; 43(8):2298-302. PubMed ID: 6714436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms.
    Sindrup SH; Brøsen K; Hansen MG; Aaes-Jørgensen T; Overø KF; Gram LF
    Ther Drug Monit; 1993 Feb; 15(1):11-7. PubMed ID: 8451774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.